Skip to main content
Erschienen in: Der Hautarzt 8/2020

24.06.2020 | Plattenepithelkarzinom der Haut | Leitthema

Kutanes Plattenepithelkarzinom

verfasst von: Prof. Dr. med. U. Leiter, R. Gutzmer, M. Alter, C. Ulrich, A. Meiwes, M. V. Heppt, T. Steeb, C. Berking, A. S. Lonsdorf, M. M. Sachse, C. Garbe, U. Hillen

Erschienen in: Die Dermatologie | Ausgabe 8/2020

Einloggen, um Zugang zu erhalten

Zusammenfassung

Das Plattenepithelkarzinom der Haut ist eine der häufigsten Krebsarten der kaukasischen Population und umfasst 20 % aller Hauttumoren. Seit 2019 liegt eine S3-Leitlinie des deutschen Leitlinienprogramms Onkologie vor. Die Diagnose basiert auf der klinischen Untersuchung. Eine Exzision und histologische Sicherung ist bei allen klinisch verdächtigen Läsionen erforderlich, um eine prognostische Einschätzung und korrekte Behandlung zu ermöglichen. Die Therapie der ersten Wahl ist die vollständige Exzision mit histologischer Schnittrandkontrolle. Bei kutanen Plattenepithelkarzinomen mit Risikofaktoren wie einer Tumordicke >6 mm kann eine Sentinellymphknotenbiopsie diskutiert werden, derzeit gibt es aber noch keine klare Evidenz bezüglich der prognostischen und therapeutischen Bedeutung. Eine adjuvante Radiatio kann bei hohem Rezidivrisiko erwogen und sollte bei inoperablen Tumoren geprüft werden. Zur Therapie eines inoperablen lokalen bzw. lokoregionären Rezidivs sollte auch die Indikation zur Elektrochemotherapie geprüft werden. Bei inoperablen oder metastasierten Plattenepithelkarzinomen ist der Immuncheckpointinhibitor Cemiplimab zugelassen. Bei Kontraindikationen können Chemotherapeutika, EGFR(„epidermal growth factor receptor“)-Inhibitoren oder eine palliative Radiatio eingesetzt werden. Da die Evidenz hier gering ist, sollte eine Systemtherapie vorzugsweise in klinischen Studien erfolgen. Die Nachsorge sollte risikoadaptiert stattfinden und schließt eine dermatologische Kontrolle ergänzt um Ultraschalluntersuchungen bei Hochrisikopatienten ein.
Literatur
1.
Zurück zum Zitat DDG, ADPA (2014) S3-LeitliniePrävention von Hautkrebs. Leitlinienprogramm Onkologie. DDG, ADPA (2014) S3-LeitliniePrävention von Hautkrebs. Leitlinienprogramm Onkologie.
2.
Zurück zum Zitat Ajithkumar TV, Parkinson CA, Butler A, Hatcher HM (2007) Management of solid tumours in organ-transplant recipients. Lancet Oncol 8:921–932PubMed Ajithkumar TV, Parkinson CA, Butler A, Hatcher HM (2007) Management of solid tumours in organ-transplant recipients. Lancet Oncol 8:921–932PubMed
3.
Zurück zum Zitat Alter M, Satzger I, Schrem H, Kaltenborn A, Kapp A, Gutzmer R (2014) Non-melanoma skin cancer is reduced after switch of immunosuppression to mTOR-inhibitors in organ transplant recipients. J Dtsch Dermatol Ges 12:480–488PubMed Alter M, Satzger I, Schrem H, Kaltenborn A, Kapp A, Gutzmer R (2014) Non-melanoma skin cancer is reduced after switch of immunosuppression to mTOR-inhibitors in organ transplant recipients. J Dtsch Dermatol Ges 12:480–488PubMed
4.
Zurück zum Zitat Brantsch KD, Meisner C, Schonfisch B, Trilling B, Wehner-Caroli J, Rocken M, Breuninger H (2008) Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol 9:713–720PubMed Brantsch KD, Meisner C, Schonfisch B, Trilling B, Wehner-Caroli J, Rocken M, Breuninger H (2008) Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol 9:713–720PubMed
5.
Zurück zum Zitat Brenn T (2020) Soft tissue special issue: cutaneous pleomorphic spindle cell tumors. Head Neck Pathol 14:109–120PubMed Brenn T (2020) Soft tissue special issue: cutaneous pleomorphic spindle cell tumors. Head Neck Pathol 14:109–120PubMed
6.
Zurück zum Zitat Breuninger H, Eigentler T, Hafner HM, Leiter U (2019) Local surgical treatment of cutaneous squamous cell carcinoma: deficits and controversies in the literature. J Dtsch Dermatol Ges 17:999–1004PubMed Breuninger H, Eigentler T, Hafner HM, Leiter U (2019) Local surgical treatment of cutaneous squamous cell carcinoma: deficits and controversies in the literature. J Dtsch Dermatol Ges 17:999–1004PubMed
7.
Zurück zum Zitat Campana LG, Edhemovic I, Soden D, Perrone AM, Scarpa M, Campanacci L, Cemazar M, Valpione S, Miklavcic D, Mocellin S, Sieni E, Sersa G (2019) Electrochemotherapy—Emerging applications technical advances, new indications, combined approaches, and multi-institutional collaboration. Eur J Surg Oncol 45:92–102PubMed Campana LG, Edhemovic I, Soden D, Perrone AM, Scarpa M, Campanacci L, Cemazar M, Valpione S, Miklavcic D, Mocellin S, Sieni E, Sersa G (2019) Electrochemotherapy—Emerging applications technical advances, new indications, combined approaches, and multi-institutional collaboration. Eur J Surg Oncol 45:92–102PubMed
8.
Zurück zum Zitat Cartei G, Cartei F, Interlandi G, Meneghini G, Jop A, Zingone G, Tabaro G, Mazzoleni F (2000) Oral 5‑fluorouracil in squamous cell carcinoma of the skin in the aged. Am J Clin Oncol 23:181–184PubMed Cartei G, Cartei F, Interlandi G, Meneghini G, Jop A, Zingone G, Tabaro G, Mazzoleni F (2000) Oral 5‑fluorouracil in squamous cell carcinoma of the skin in the aged. Am J Clin Oncol 23:181–184PubMed
9.
Zurück zum Zitat Chen AC, Martin AJ, Choy B, Fernandez-Penas P, Dalziell RA, McKenzie CA, Scolyer RA, Dhillon HM, Vardy JL, Kricker A, George StG, Chinniah N, Halliday GM, Damian DL (2015) A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention. N Engl J Med 373:1618–1626 Chen AC, Martin AJ, Choy B, Fernandez-Penas P, Dalziell RA, McKenzie CA, Scolyer RA, Dhillon HM, Vardy JL, Kricker A, George StG, Chinniah N, Halliday GM, Damian DL (2015) A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention. N Engl J Med 373:1618–1626
11.
Zurück zum Zitat Elder DE, Bastian BC, Cree IA, Massi D, Scolyer RA (2020) The 2018 world health organization classification of cutaneous, mucosal, and uveal melanoma: detailed analysis of 9 distinct subtypes defined by their evolutionary pathway. Arch Pathol Lab Med 144:500–522PubMed Elder DE, Bastian BC, Cree IA, Massi D, Scolyer RA (2020) The 2018 world health organization classification of cutaneous, mucosal, and uveal melanoma: detailed analysis of 9 distinct subtypes defined by their evolutionary pathway. Arch Pathol Lab Med 144:500–522PubMed
12.
Zurück zum Zitat English DR, Armstrong BK, Kricker A, Winter MG, Heenan PJ, Randell PL (1998) Demographic characteristics, pigmentary and cutaneous risk factors for squamous cell carcinoma of the skin: A case-control study. Int J Cancer 76:628–634PubMed English DR, Armstrong BK, Kricker A, Winter MG, Heenan PJ, Randell PL (1998) Demographic characteristics, pigmentary and cutaneous risk factors for squamous cell carcinoma of the skin: A case-control study. Int J Cancer 76:628–634PubMed
13.
Zurück zum Zitat Euvrard S, Morelon E, Rostaing L, Goffin E, Brocard A, Tromme I, Broeders N, del MV, Chatelet V, Dompmartin A, Kessler M, Serra AL, Hofbauer GF, Pouteil-Noble C, Campistol JM, Kanitakis J, Roux AS, Decullier E, Dantal J (2012) Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med 367:329–339PubMed Euvrard S, Morelon E, Rostaing L, Goffin E, Brocard A, Tromme I, Broeders N, del MV, Chatelet V, Dompmartin A, Kessler M, Serra AL, Hofbauer GF, Pouteil-Noble C, Campistol JM, Kanitakis J, Roux AS, Decullier E, Dantal J (2012) Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med 367:329–339PubMed
14.
Zurück zum Zitat Foote MC, McGrath M, Guminski A, Hughes BG, Meakin J, Thomson D, Zarate D, Simpson F, Porceddu SV (2014) Phase II study of single-agent panitumumab in patients with incurable cutaneous squamous cell carcinoma. Ann Oncol 25:2047–2052PubMed Foote MC, McGrath M, Guminski A, Hughes BG, Meakin J, Thomson D, Zarate D, Simpson F, Porceddu SV (2014) Phase II study of single-agent panitumumab in patients with incurable cutaneous squamous cell carcinoma. Ann Oncol 25:2047–2052PubMed
15.
Zurück zum Zitat Grager N, Leffler M, Gottlieb J, Fuge J, Warnecke G, Gutzmer R, Satzger I (2019) Risk factors for developing nonmelanoma skin cancer after lung transplantation. J Skin Cancer 2019:7089482PubMedPubMedCentral Grager N, Leffler M, Gottlieb J, Fuge J, Warnecke G, Gutzmer R, Satzger I (2019) Risk factors for developing nonmelanoma skin cancer after lung transplantation. J Skin Cancer 2019:7089482PubMedPubMedCentral
16.
Zurück zum Zitat Gurney B, Newlands C (2014) Management of regional metastatic disease in head and neck cutaneous malignancy. 1. Cutaneous squamous cell carcinoma. Br J Oral Maxillofac Surg 52:294–300PubMed Gurney B, Newlands C (2014) Management of regional metastatic disease in head and neck cutaneous malignancy. 1. Cutaneous squamous cell carcinoma. Br J Oral Maxillofac Surg 52:294–300PubMed
17.
Zurück zum Zitat Guthrie TH Jr., Porubsky ES, Luxenberg MN, Shah KJ, Wurtz KL, Watson PR (1990) Cisplatin-based chemotherapy in advanced basal and squamous cell carcinomas of the skin: results in 28 patients including 13 patients receiving multimodality therapy. J Clin Oncol 8:342–346PubMed Guthrie TH Jr., Porubsky ES, Luxenberg MN, Shah KJ, Wurtz KL, Watson PR (1990) Cisplatin-based chemotherapy in advanced basal and squamous cell carcinomas of the skin: results in 28 patients including 13 patients receiving multimodality therapy. J Clin Oncol 8:342–346PubMed
18.
Zurück zum Zitat Gutzmer R, Becker JC (2019) J Dtsch Dermatol Ges 17:1097–1098PubMed Gutzmer R, Becker JC (2019) J Dtsch Dermatol Ges 17:1097–1098PubMed
19.
Zurück zum Zitat Han A, Ratner D (2007) What is the role of adjuvant radiotherapy in the treatment of cutaneous squamous cell carcinoma with perineural invasion? Cancer 109:1053–1059PubMed Han A, Ratner D (2007) What is the role of adjuvant radiotherapy in the treatment of cutaneous squamous cell carcinoma with perineural invasion? Cancer 109:1053–1059PubMed
21.
Zurück zum Zitat Heath CH, Deep NL, Nabell L, Carroll WR, Desmond R, Clemons L, Spencer S, Magnuson JS, Rosenthal EL (2013) Phase 1 study of erlotinib plus radiation therapy in patients with advanced cutaneous squamous cell carcinoma. Int J Radiat Oncol Biol Phys 85:1275–1281PubMed Heath CH, Deep NL, Nabell L, Carroll WR, Desmond R, Clemons L, Spencer S, Magnuson JS, Rosenthal EL (2013) Phase 1 study of erlotinib plus radiation therapy in patients with advanced cutaneous squamous cell carcinoma. Int J Radiat Oncol Biol Phys 85:1275–1281PubMed
22.
Zurück zum Zitat Heppt MV, Leiter U, Steeb T, Amaral T, Bauer A, Becker JC, Breitbart E, Breuninger H, Diepgen T, Dirschka T, Eigentler T, Flaig M, Follmann M, Fritz K, Greinert R, Gutzmer R, Hillen U, Ihrler S, John SM, Kolbl O, Kraywinkel K, Loser C, Nashan D, Noor S, Nothacker M, Pfannenberg C, Salavastru C, Schmitz L, Stockfleth E, Szeimies RM, Ulrich C, Welzel J, Wermker K, Berking C, Garbe C (2020) S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma—short version, part 1: diagnosis, interventions for actinic keratoses, care structures and quality-of-care indicators. J Dtsch Dermatol Ges 18:275–294PubMed Heppt MV, Leiter U, Steeb T, Amaral T, Bauer A, Becker JC, Breitbart E, Breuninger H, Diepgen T, Dirschka T, Eigentler T, Flaig M, Follmann M, Fritz K, Greinert R, Gutzmer R, Hillen U, Ihrler S, John SM, Kolbl O, Kraywinkel K, Loser C, Nashan D, Noor S, Nothacker M, Pfannenberg C, Salavastru C, Schmitz L, Stockfleth E, Szeimies RM, Ulrich C, Welzel J, Wermker K, Berking C, Garbe C (2020) S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma—short version, part 1: diagnosis, interventions for actinic keratoses, care structures and quality-of-care indicators. J Dtsch Dermatol Ges 18:275–294PubMed
23.
Zurück zum Zitat Hillen U, Leiter U, Haase S, Kaufmann R, Becker J, Gutzmer R, Terheyden P, Krause-Bergmann A, Schulze HJ, Hassel J, Lahner N, Wollina U, Ziller F, Utikal J, Hafner C, Ulrich J, Machens HG, Weishaupt C, Hauschild A, Mohr P, Pfohler C, Maurer J, Wolff P, Windemuth-Kieselbach C, Schadendorf D, Livingstone E (2018) Advanced cutaneous squamous cell carcinoma: A retrospective analysis of patient profiles and treatment patterns-Results of a non-interventional study of the DeCOG. Eur J Cancer 96:34–43PubMed Hillen U, Leiter U, Haase S, Kaufmann R, Becker J, Gutzmer R, Terheyden P, Krause-Bergmann A, Schulze HJ, Hassel J, Lahner N, Wollina U, Ziller F, Utikal J, Hafner C, Ulrich J, Machens HG, Weishaupt C, Hauschild A, Mohr P, Pfohler C, Maurer J, Wolff P, Windemuth-Kieselbach C, Schadendorf D, Livingstone E (2018) Advanced cutaneous squamous cell carcinoma: A retrospective analysis of patient profiles and treatment patterns-Results of a non-interventional study of the DeCOG. Eur J Cancer 96:34–43PubMed
24.
Zurück zum Zitat Hillen U, Ulrich M, Alter M, Becker JC, Gutzmer R, Leiter U, Lonsdorf A, Messerschmidt A, Ulrich C (2014) Cutaneous squamous cell carcinoma: A review with consideration of special patient groups. Hautarzt 65:590–599PubMed Hillen U, Ulrich M, Alter M, Becker JC, Gutzmer R, Leiter U, Lonsdorf A, Messerschmidt A, Ulrich C (2014) Cutaneous squamous cell carcinoma: A review with consideration of special patient groups. Hautarzt 65:590–599PubMed
25.
Zurück zum Zitat Hollestein LM, de Vries E, Nijsten T (2012) Trends of cutaneous squamous cell carcinoma in the Netherlands: Increased incidence rates, but stable relative survival and mortality 1989–2008. Eur J Cancer 48:2046–2053PubMed Hollestein LM, de Vries E, Nijsten T (2012) Trends of cutaneous squamous cell carcinoma in the Netherlands: Increased incidence rates, but stable relative survival and mortality 1989–2008. Eur J Cancer 48:2046–2053PubMed
26.
Zurück zum Zitat Jambusaria-Pahlajani A, Miller CJ, Quon H, Smith N, Klein RQ, Schmults CD (2009) Surgical monotherapy versus surgery plus adjuvant radiotherapy in high-risk cutaneous squamous cell carcinoma: a systematic review of outcomes. Dermatol Surg 35:574–585PubMed Jambusaria-Pahlajani A, Miller CJ, Quon H, Smith N, Klein RQ, Schmults CD (2009) Surgical monotherapy versus surgery plus adjuvant radiotherapy in high-risk cutaneous squamous cell carcinoma: a systematic review of outcomes. Dermatol Surg 35:574–585PubMed
27.
Zurück zum Zitat Jenni D, Karpova MB, Muhleisen B, Mangana J, Dreier J, Hafner J, Dummer R (2016) A prospective clinical trial to assess lapatinib effects on cutaneous squamous cell carcinoma and actinic keratosis. ESMO Open 1:e3PubMedPubMedCentral Jenni D, Karpova MB, Muhleisen B, Mangana J, Dreier J, Hafner J, Dummer R (2016) A prospective clinical trial to assess lapatinib effects on cutaneous squamous cell carcinoma and actinic keratosis. ESMO Open 1:e3PubMedPubMedCentral
28.
Zurück zum Zitat Karia PS, Han J, Schmults CD (2013) Cutaneous squamous cell carcinoma: Estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012. J Am Acad Dermatol 68:957–966PubMed Karia PS, Han J, Schmults CD (2013) Cutaneous squamous cell carcinoma: Estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012. J Am Acad Dermatol 68:957–966PubMed
29.
Zurück zum Zitat Keim U, van der Pols JC, Williams GM, Green AC (2015) Exclusive development of a single type of keratinocyte skin cancer: evidence from an Australian population-based cohort study. J Invest Dermatol 135:728–733PubMed Keim U, van der Pols JC, Williams GM, Green AC (2015) Exclusive development of a single type of keratinocyte skin cancer: evidence from an Australian population-based cohort study. J Invest Dermatol 135:728–733PubMed
30.
Zurück zum Zitat Khansur T, Kennedy A (1991) Cisplatin and 5‑fluorouracil for advanced locoregional and metastatic squamous cell carcinoma of the skin. Cancer 67:2030–2032PubMed Khansur T, Kennedy A (1991) Cisplatin and 5‑fluorouracil for advanced locoregional and metastatic squamous cell carcinoma of the skin. Cancer 67:2030–2032PubMed
31.
Zurück zum Zitat Kreuter A, van Eijk T, Lehmann P, Fischer M, Horn T, Assaf C, Schley G, Herbst R, Kellner I, Weisbrich C, Hyun J, Wieland U, Schlaak M, Rubben A, Lommel K (2015) Electrochemotherapy in advanced skin tumors and cutaneous metastases—a retrospective multicenter analysis. J Dtsch Dermatol Ges 13:308–315PubMed Kreuter A, van Eijk T, Lehmann P, Fischer M, Horn T, Assaf C, Schley G, Herbst R, Kellner I, Weisbrich C, Hyun J, Wieland U, Schlaak M, Rubben A, Lommel K (2015) Electrochemotherapy in advanced skin tumors and cutaneous metastases—a retrospective multicenter analysis. J Dtsch Dermatol Ges 13:308–315PubMed
32.
Zurück zum Zitat Krynitz B, Edgren G, Lindelof B, Baecklund E, Brattstrom C, Wilczek H, Smedby KE (2013) Risk of skin cancer and other malignancies in kidney, liver, heart and lung transplant recipients 1970 to 2008—a Swedish population-based study. Int J Cancer 132:1429–1438PubMed Krynitz B, Edgren G, Lindelof B, Baecklund E, Brattstrom C, Wilczek H, Smedby KE (2013) Risk of skin cancer and other malignancies in kidney, liver, heart and lung transplant recipients 1970 to 2008—a Swedish population-based study. Int J Cancer 132:1429–1438PubMed
33.
Zurück zum Zitat Leiter U, Eigentler T, Garbe C (2014) Epidemiology of skin cancer. Adv Exp Med Biol 810:120–140PubMed Leiter U, Eigentler T, Garbe C (2014) Epidemiology of skin cancer. Adv Exp Med Biol 810:120–140PubMed
34.
Zurück zum Zitat Leiter U, Heppt MV, Steeb T, Amaral T, Bauer A, Becker JC, Breitbart E, Breuninger H, Diepgen T, Dirschka T, Eigentler T, Flaig M, Follmann M, Fritz K, Greinert R, Gutzmer R, Hillen U, Ihrler S, John SM, Kolbl O, Kraywinkel K, Loser C, Nashan D, Noor S, Nothacker M, Pfannenberg C, Salavastru C, Schmitz L, Stockfleth E, Szeimies RM, Ulrich C, Welzel J, Wermker K, Garbe C, Berking C (2020) S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma (cSCC)—short version, part 2: epidemiology, surgical and systemic treatment of cSCC, follow-up, prevention and occupational disease. J Dtsch Dermatol Ges. https://doi.org/10.1111/ddg.14072 CrossRefPubMed Leiter U, Heppt MV, Steeb T, Amaral T, Bauer A, Becker JC, Breitbart E, Breuninger H, Diepgen T, Dirschka T, Eigentler T, Flaig M, Follmann M, Fritz K, Greinert R, Gutzmer R, Hillen U, Ihrler S, John SM, Kolbl O, Kraywinkel K, Loser C, Nashan D, Noor S, Nothacker M, Pfannenberg C, Salavastru C, Schmitz L, Stockfleth E, Szeimies RM, Ulrich C, Welzel J, Wermker K, Garbe C, Berking C (2020) S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma (cSCC)—short version, part 2: epidemiology, surgical and systemic treatment of cSCC, follow-up, prevention and occupational disease. J Dtsch Dermatol Ges. https://​doi.​org/​10.​1111/​ddg.​14072 CrossRefPubMed
35.
Zurück zum Zitat Leiter U, Keim U, Eigentler T, Katalinic A, Holleczek B, Martus P, Garbe C (2017) Incidence, mortality, and trends of nonmelanoma skin cancer in Germany. J Invest Dermatol 137:1860–1867PubMed Leiter U, Keim U, Eigentler T, Katalinic A, Holleczek B, Martus P, Garbe C (2017) Incidence, mortality, and trends of nonmelanoma skin cancer in Germany. J Invest Dermatol 137:1860–1867PubMed
36.
Zurück zum Zitat Lewis CM, Glisson BS, Feng L, Wan F, Tang X, Wistuba II, El Naggar AK, Rosenthal DI, Chambers MS, Lustig RA, Weber RS (2012) A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck. Clin Cancer Res 18:1435–1446PubMedPubMedCentral Lewis CM, Glisson BS, Feng L, Wan F, Tang X, Wistuba II, El Naggar AK, Rosenthal DI, Chambers MS, Lustig RA, Weber RS (2012) A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck. Clin Cancer Res 18:1435–1446PubMedPubMedCentral
37.
Zurück zum Zitat Lippman SM, Parkinson DR, Itri LM, Weber RS, Schantz SP, Ota DM, Schusterman MA, Krakoff IH, Gutterman JU, Hong WK (1992) 13-cis-retinoic acid and interferon alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst 84:235–241PubMed Lippman SM, Parkinson DR, Itri LM, Weber RS, Schantz SP, Ota DM, Schusterman MA, Krakoff IH, Gutterman JU, Hong WK (1992) 13-cis-retinoic acid and interferon alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst 84:235–241PubMed
38.
Zurück zum Zitat Martincorena I, Roshan A, Gerstung M, Ellis P, Van Loo P, McLaren S, Wedge DC, Fullam A, Alexandrov LB, Tubio JM, Stebbings L, Menzies A, Widaa S, Stratton MR, Jones PH, Campbell PJ (2015) Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin. Science 348:880–886PubMedPubMedCentral Martincorena I, Roshan A, Gerstung M, Ellis P, Van Loo P, McLaren S, Wedge DC, Fullam A, Alexandrov LB, Tubio JM, Stebbings L, Menzies A, Widaa S, Stratton MR, Jones PH, Campbell PJ (2015) Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin. Science 348:880–886PubMedPubMedCentral
39.
Zurück zum Zitat Martinez LS, Schwartz JS, Freres D, Fraze T, Hornik RC (2009) Patient-clinician information engagement increases treatment decision satisfaction among cancer patients through feeling of being informed. Patient Educ Couns 77:384–390PubMedPubMedCentral Martinez LS, Schwartz JS, Freres D, Fraze T, Hornik RC (2009) Patient-clinician information engagement increases treatment decision satisfaction among cancer patients through feeling of being informed. Patient Educ Couns 77:384–390PubMedPubMedCentral
40.
Zurück zum Zitat Maubec E, Petrow P, Scheer-Senyarich I, Duvillard P, Lacroix L, Gelly J, Certain A, Duval X, Crickx B, Buffard V, Basset-Seguin N, Saez P, Duval-Modeste AB, Adamski H, Mansard S, Grange F, Dompmartin A, Faivre S, Mentre F, Avril MF (2011) Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol 29:3419–3426PubMed Maubec E, Petrow P, Scheer-Senyarich I, Duvillard P, Lacroix L, Gelly J, Certain A, Duval X, Crickx B, Buffard V, Basset-Seguin N, Saez P, Duval-Modeste AB, Adamski H, Mansard S, Grange F, Dompmartin A, Faivre S, Mentre F, Avril MF (2011) Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol 29:3419–3426PubMed
41.
Zurück zum Zitat Migden MR, Khushalani NI, Chang ALS, Lewis KD, Schmults CD, Hernandez-Aya L, Meier F, Schadendorf D, Guminski A, Hauschild A, Wong DJ, Daniels GA, Berking C, Jankovic V, Stankevich E, Booth J, Li S, Weinreich DM, Yancopoulos GD, Lowy I, Fury MG, Rischin D (2020) Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. Lancet Oncol 21:294–305PubMed Migden MR, Khushalani NI, Chang ALS, Lewis KD, Schmults CD, Hernandez-Aya L, Meier F, Schadendorf D, Guminski A, Hauschild A, Wong DJ, Daniels GA, Berking C, Jankovic V, Stankevich E, Booth J, Li S, Weinreich DM, Yancopoulos GD, Lowy I, Fury MG, Rischin D (2020) Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. Lancet Oncol 21:294–305PubMed
42.
Zurück zum Zitat Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, Chung CH, Hernandez-Aya L, Lim AM, Chang ALS, Rabinowits G, Thai AA, Dunn LA, Hughes BGM, Khushalani NI, Modi B, Schadendorf D, Gao B, Seebach F, Li S, Li J, Mathias M, Booth J, Mohan K, Stankevich E, Babiker HM, Brana I, Gil-Martin M, Homsi J, Johnson ML, Moreno V, Niu J, Owonikoko TK, Papadopoulos KP, Yancopoulos GD, Lowy I, Fury MG (2018) PD‑1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med 379:341–351PubMed Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, Chung CH, Hernandez-Aya L, Lim AM, Chang ALS, Rabinowits G, Thai AA, Dunn LA, Hughes BGM, Khushalani NI, Modi B, Schadendorf D, Gao B, Seebach F, Li S, Li J, Mathias M, Booth J, Mohan K, Stankevich E, Babiker HM, Brana I, Gil-Martin M, Homsi J, Johnson ML, Moreno V, Niu J, Owonikoko TK, Papadopoulos KP, Yancopoulos GD, Lowy I, Fury MG (2018) PD‑1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med 379:341–351PubMed
43.
Zurück zum Zitat Motaparthi K, Kapil JP, Velazquez EF (2017) Cutaneous squamous cell carcinoma: review of the eighth edition of the American Joint Committee on cancer staging guidelines, prognostic factors, and Histopathologic variants. Adv Anat Pathol 24:171–194PubMed Motaparthi K, Kapil JP, Velazquez EF (2017) Cutaneous squamous cell carcinoma: review of the eighth edition of the American Joint Committee on cancer staging guidelines, prognostic factors, and Histopathologic variants. Adv Anat Pathol 24:171–194PubMed
44.
Zurück zum Zitat Newlands C, Currie R, Memon A, Whitaker S, Woolford T (2016) Non-melanoma skin cancer: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol 130:S125–S132PubMedPubMedCentral Newlands C, Currie R, Memon A, Whitaker S, Woolford T (2016) Non-melanoma skin cancer: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol 130:S125–S132PubMedPubMedCentral
45.
Zurück zum Zitat Nottage MK, Lin C, Hughes BG, Kenny L, Smith DD, Houston K, Francesconi A (2017) Prospective study of definitive chemoradiation in locally or regionally advanced squamous cell carcinoma of the skin. Head Neck 39:679–683PubMed Nottage MK, Lin C, Hughes BG, Kenny L, Smith DD, Houston K, Francesconi A (2017) Prospective study of definitive chemoradiation in locally or regionally advanced squamous cell carcinoma of the skin. Head Neck 39:679–683PubMed
46.
Zurück zum Zitat Renzi C, Caggiati A, Mannooranparampil TJ, Passarelli F, Tartaglione G, Pennasilico GM, Cecconi S, Potenza C, Pasquini P (2007) Sentinel lymph node biopsy for high risk cutaneous squamous cell carcinoma: case series and review of the literature. Eur J Surg Oncol 33:364–369PubMed Renzi C, Caggiati A, Mannooranparampil TJ, Passarelli F, Tartaglione G, Pennasilico GM, Cecconi S, Potenza C, Pasquini P (2007) Sentinel lymph node biopsy for high risk cutaneous squamous cell carcinoma: case series and review of the literature. Eur J Surg Oncol 33:364–369PubMed
47.
Zurück zum Zitat Rettberg P, Horneck G (1999) Intrinsic and extrinsic biomarkers for the assessment of risks from environmental UV radiation. J Epidemiol 9:S78–S83PubMed Rettberg P, Horneck G (1999) Intrinsic and extrinsic biomarkers for the assessment of risks from environmental UV radiation. J Epidemiol 9:S78–S83PubMed
48.
Zurück zum Zitat Sadek H, Azli N, Wendling JL, Cvitkovic E, Rahal M, Mamelle G, Guillaume JC, Armand JP, Avril MF (1990) Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5‑fluorouracil, and bleomycin. Cancer 66:1692–1696PubMed Sadek H, Azli N, Wendling JL, Cvitkovic E, Rahal M, Mamelle G, Guillaume JC, Armand JP, Avril MF (1990) Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5‑fluorouracil, and bleomycin. Cancer 66:1692–1696PubMed
49.
Zurück zum Zitat Schmitt AR, Brewer JD, Bordeaux JS, Baum CL (2014) Staging for cutaneous squamous cell carcinoma as a predictor of sentinel lymph node biopsy results: meta-analysis of American Joint Committee on Cancer criteria and a proposed alternative system. JAMA Dermatol 150:19–24PubMed Schmitt AR, Brewer JD, Bordeaux JS, Baum CL (2014) Staging for cutaneous squamous cell carcinoma as a predictor of sentinel lymph node biopsy results: meta-analysis of American Joint Committee on Cancer criteria and a proposed alternative system. JAMA Dermatol 150:19–24PubMed
50.
Zurück zum Zitat Schmitt J, Seidler A, Diepgen TL, Bauer A (2011) Occupational ultraviolet light exposure increases the risk for the development of cutaneous squamous cell carcinoma: a systematic review and meta-analysis. Br J Dermatol 164:291–307PubMed Schmitt J, Seidler A, Diepgen TL, Bauer A (2011) Occupational ultraviolet light exposure increases the risk for the development of cutaneous squamous cell carcinoma: a systematic review and meta-analysis. Br J Dermatol 164:291–307PubMed
51.
Zurück zum Zitat Shin DM, Glisson BS, Khuri FR, Clifford JL, Clayman G, Benner SE, Forastiere AA, Ginsberg L, Liu D, Lee JJ, Myers J, Goepfert H, Lotan R, Hong WK, Lippman SM (2002) Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer. J Clin Oncol 20:364–370PubMed Shin DM, Glisson BS, Khuri FR, Clifford JL, Clayman G, Benner SE, Forastiere AA, Ginsberg L, Liu D, Lee JJ, Myers J, Goepfert H, Lotan R, Hong WK, Lippman SM (2002) Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer. J Clin Oncol 20:364–370PubMed
52.
Zurück zum Zitat Stang A (2007) Genital and nongenital nonmelanoma skin cancer: more epidemiological studies are needed. J Invest Dermatol 127:2296–2299PubMed Stang A (2007) Genital and nongenital nonmelanoma skin cancer: more epidemiological studies are needed. J Invest Dermatol 127:2296–2299PubMed
53.
Zurück zum Zitat Stratigos A, Garbe C, Lebbe C, Malvehy J, del MV, Pehamberger H, Peris K, Becker JC, Zalaudek I, Saiag P, Middleton MR, Bastholt L, Testori A, Grob JJ (2015) Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline. Eur J Cancer 51:1989–2007PubMed Stratigos A, Garbe C, Lebbe C, Malvehy J, del MV, Pehamberger H, Peris K, Becker JC, Zalaudek I, Saiag P, Middleton MR, Bastholt L, Testori A, Grob JJ (2015) Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline. Eur J Cancer 51:1989–2007PubMed
54.
Zurück zum Zitat Strunk T, Szeimies RM (2014) Actinic keratoses. Pathogenesis, clinical aspect and modern therapeutic options. Hautarzt 65:241–252PubMed Strunk T, Szeimies RM (2014) Actinic keratoses. Pathogenesis, clinical aspect and modern therapeutic options. Hautarzt 65:241–252PubMed
55.
Zurück zum Zitat Surjana D, Halliday GM, Martin AJ, Moloney FJ, Damian DL (2012) Oral nicotinamide reduces actinic keratoses in phase II double-blinded randomized controlled trials. J Invest Dermatol 132:1497–1500PubMed Surjana D, Halliday GM, Martin AJ, Moloney FJ, Damian DL (2012) Oral nicotinamide reduces actinic keratoses in phase II double-blinded randomized controlled trials. J Invest Dermatol 132:1497–1500PubMed
56.
Zurück zum Zitat Tanvetyanon T, Padhya T, McCaffrey J, Kish JA, Deconti RC, Trotti A, Rao NG (2015) Postoperative concurrent chemotherapy and radiotherapy for high-risk cutaneous squamous cell carcinoma of the head and neck. Head Neck 37:840–845PubMed Tanvetyanon T, Padhya T, McCaffrey J, Kish JA, Deconti RC, Trotti A, Rao NG (2015) Postoperative concurrent chemotherapy and radiotherapy for high-risk cutaneous squamous cell carcinoma of the head and neck. Head Neck 37:840–845PubMed
57.
Zurück zum Zitat Thompson AK, Kelley BF, Prokop LJ, Murad MH, Baum CL (2016) Risk factors for cutaneous squamous cell carcinoma recurrence, metastasis, and disease-specific death: A systematic review and Meta-analysis. JAMA Dermatol 152:419–428PubMedPubMedCentral Thompson AK, Kelley BF, Prokop LJ, Murad MH, Baum CL (2016) Risk factors for cutaneous squamous cell carcinoma recurrence, metastasis, and disease-specific death: A systematic review and Meta-analysis. JAMA Dermatol 152:419–428PubMedPubMedCentral
58.
Zurück zum Zitat Veness MJ (2005) Treatment recommendations in patients diagnosed with high-risk cutaneous squamous cell carcinoma. Australas Radiol 49:365–376PubMed Veness MJ (2005) Treatment recommendations in patients diagnosed with high-risk cutaneous squamous cell carcinoma. Australas Radiol 49:365–376PubMed
59.
Zurück zum Zitat Veness MJ, Morgan GJ, Palme CE, Gebski V (2005) Surgery and adjuvant radiotherapy in patients with cutaneous head and neck squamous cell carcinoma metastatic to lymph nodes: combined treatment should be considered best practice. Laryngoscope 115:870–875PubMed Veness MJ, Morgan GJ, Palme CE, Gebski V (2005) Surgery and adjuvant radiotherapy in patients with cutaneous head and neck squamous cell carcinoma metastatic to lymph nodes: combined treatment should be considered best practice. Laryngoscope 115:870–875PubMed
60.
Zurück zum Zitat Veness MJ, Palme CE, Smith M, Cakir B, Morgan GJ, Kalnins I (2003) Cutaneous head and neck squamous cell carcinoma metastatic to cervical lymph nodes (nonparotid): a better outcome with surgery and adjuvant radiotherapy. Laryngoscope 113:1827–1833PubMed Veness MJ, Palme CE, Smith M, Cakir B, Morgan GJ, Kalnins I (2003) Cutaneous head and neck squamous cell carcinoma metastatic to cervical lymph nodes (nonparotid): a better outcome with surgery and adjuvant radiotherapy. Laryngoscope 113:1827–1833PubMed
61.
Zurück zum Zitat Wang JT, Palme CE, Morgan GJ, Gebski V, Wang AY, Veness MJ (2012) Predictors of outcome in patients with metastatic cutaneous head and neck squamous cell carcinoma involving cervical lymph nodes: Improved survival with the addition of adjuvant radiotherapy. Head Neck 34:1524–1528PubMed Wang JT, Palme CE, Morgan GJ, Gebski V, Wang AY, Veness MJ (2012) Predictors of outcome in patients with metastatic cutaneous head and neck squamous cell carcinoma involving cervical lymph nodes: Improved survival with the addition of adjuvant radiotherapy. Head Neck 34:1524–1528PubMed
62.
Zurück zum Zitat Waxweiler W, Sigmon JR, Sheehan DJ (2011) Adjunctive radiotherapy in the treatment of cutaneous squamous cell carcinoma with perineural invasion. J Surg Oncol 104:104–105PubMed Waxweiler W, Sigmon JR, Sheehan DJ (2011) Adjunctive radiotherapy in the treatment of cutaneous squamous cell carcinoma with perineural invasion. J Surg Oncol 104:104–105PubMed
63.
Zurück zum Zitat Weedon DMR, Kao GF, Harwood CA (2006) Keratinocytic tumors. IARC Press, Lyon Weedon DMR, Kao GF, Harwood CA (2006) Keratinocytic tumors. IARC Press, Lyon
64.
Zurück zum Zitat Wulff BC, Kusewitt DF, VanBuskirk AM, Thomas-Ahner JM, Duncan FJ, Oberyszyn TM (2008) Sirolimus reduces the incidence and progression of UVB-induced skin cancer in SKH mice even with co-administration of cyclosporine A. J Invest Dermatol 128:2467–2473PubMedPubMedCentral Wulff BC, Kusewitt DF, VanBuskirk AM, Thomas-Ahner JM, Duncan FJ, Oberyszyn TM (2008) Sirolimus reduces the incidence and progression of UVB-induced skin cancer in SKH mice even with co-administration of cyclosporine A. J Invest Dermatol 128:2467–2473PubMedPubMedCentral
65.
Zurück zum Zitat Xiang F, Lucas R, Hales S, Neale R (2014) Incidence of nonmelanoma skin cancer in relation to ambient UV radiation in white populations, 1978–2012: empirical relationships. JAMA Dermatol 150:1063–1071PubMed Xiang F, Lucas R, Hales S, Neale R (2014) Incidence of nonmelanoma skin cancer in relation to ambient UV radiation in white populations, 1978–2012: empirical relationships. JAMA Dermatol 150:1063–1071PubMed
Metadaten
Titel
Kutanes Plattenepithelkarzinom
verfasst von
Prof. Dr. med. U. Leiter
R. Gutzmer
M. Alter
C. Ulrich
A. Meiwes
M. V. Heppt
T. Steeb
C. Berking
A. S. Lonsdorf
M. M. Sachse
C. Garbe
U. Hillen
Publikationsdatum
24.06.2020
Verlag
Springer Medizin
Erschienen in
Die Dermatologie / Ausgabe 8/2020
Print ISSN: 2731-7005
Elektronische ISSN: 2731-7013
DOI
https://doi.org/10.1007/s00105-020-04620-4

Weitere Artikel der Ausgabe 8/2020

Der Hautarzt 8/2020 Zur Ausgabe

Passend zum Thema

ANZEIGE

Umfrage: Topika mit Dexpanthenol bei Radiodermatitis empfohlen

In der topischen Prävention der akuten Radiodermatitis werden Zubereitungen mit Dexpanthenol oder Harnstoff von deutschsprachigen Fachkreisen in der Radioonkologie am häufigsten empfohlen und als am wirksamsten bewertet. Bei der Behandlung der strahlenbedingten Hautschäden liegen Topika mit Dexpanthenol oder Kortikosteroide vorn [1]. 

ANZEIGE

Handekzem: Adhärenz bei topischer Therapie nicht zufriedenstellend

Einer klinischen Studie zufolge wendet nur etwa die Hälfte der Ekzem-Patient:innen ihre topische Therapie mit Kortikosteroiden wie verordnet an. Darüber hinaus nahm die Adhärenz im Zeitverlauf weiter ab. Bei einer gleichzeitig applizierten barrierestabilisierenden Basiscreme blieb die Anwendungsfrequenz dagegen über die Zeit stabil [1]. 

ANZEIGE

Bepanthen® unterstützt bei vielen Indikationen die Regeneration der Haut

Content Hub

Bepanthen® Wund- und Heilsalbe wird heute wie bei der Einführung vor 70 Jahren erfolgreich bei kleinen Alltagsverletzungen eingesetzt. Moderne Forschung – Untersuchungen an Hautmodellen, Genexpressionsanalysen und klinische Studien – schafft darüber hinaus Evidenz für neue Anwendungsgebiete. So kann die Dexpanthenol-haltige Salbe heute z.B. zur Nachbehandlung einer Lasertherapie bei aktinischer Keratose oder Tattoo-Entfernung eingesetzt werden. Erfahren Sie hier mehr über moderne Forschung zu Bepanthen.

Bayer Vital GmbH